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Introduction
In a modern world, what is the best way to deliver medicines to the patient? Human
beings are an extremely diverse species with many different factors that can
influence the behaviour of a drug within the body. Children are a perfect example
of such variety. Doses are often prescribed based on body weight, and can vary
greatly from infants to adolescents. With current µWUDGLWLRQDO¶ manufacture of oral
dose pharmaceuticals, generally only a limited number of doses are produced,
leading to difficulties with appropriate dosing. The ability to manufacture
personalised doses for these patients would be of great benefit both practically and
financially, and may even lead to µSRLQW of FDUH¶manufacture.
Materials and Methods
Fused Filament Fabrication (FFF) is a technique which allows for the creation of a
3D object, layer by layer, by melting a polymer.
1Goyanes A. et al. Effect of geometry on drug release from 3D printed tablets, Int. J. Pharm. 494, 657-663 (2015)..
2 Goyanes A. et al. Fused-filament 3D printing (3DP) for fabrication of tablets, Int. J. Pharm. 476, 88-92 (2014).
Results
HPLC was used to determine drug content of both filament and printed tablets
(n = 3).
 3.58 %w/w  0.06 filament.
 9 mg  0.5 mg 30% infill tablet.
xRPD showed no peaks corresponding to the API in the final product, it is
thought the API is amorphous.
SEM analysis was carried out on blank (left) and drug loaded (right) tablets. Both
show evidence of residual solvent as seen by rough edges and pores.
While TOF-SIMS analysis also provided data on drug content, it is not possible
to ascertain the exact depth to which the API penetrates. It is hoped future
analysis with nanoCT can provide a better idea of the distribution of API with
the polymer.
Conclusions and Future Work
While fused filament fabrication is still in its infancy, it is clear that there is
potential for this technique to be used as a way of manufacturing personalised
medicine. The work presented here only demonstrates doses which can be
achieved by printing one particular size of tablet with an infill percentage of 30%.
By altering the size of this tablet, or the infill percentage, a larger range of doses
could potentially be manufactured in a reproducible manner. Varying the length
of time for submersion of the filament would not only alter the drug distribution,
but could potentially provide increased or decreased doses compared to those
reported here. If the drug is present in an amorphous state, this technique also
offers the benefit of potentially improving the dissolution rate of a BCS Class II
drug. Further studies will focus on increasing and decreasing the size and infill
percentage of printed tablets in order to further investigate the reproducibility.
There are two different ways to load a selected polymer with drug:
- Extrude the drug and polymer together using a hot-melt extruder (shown below)
to produce a filament, then transfer this to the 3D printer.1
- Obtain a polymer which is already in a filament form and load this with drug by
submerging in a solution containing the API of choice. Evaporate the remaining
solvent by heating in an oven, then transfer this to the 3D printer.2
Both have advantages and limitations. The work presented here was carried out
using the latter technique.
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